PulseSight Therapeutics SAS receives funds to support clinical trials of PST-611

(Image Credit: AdobeStock/Garmon)

PulseSight Therapeutics SAS shares that it has completed the first close of its Series A financing. Existing investor, Pureos BioVentures, is committing new funds to support the Phase I study of PST-611 and enable preparation for a Phase IIa clinical trial.

The company’s candidate for the treatment of dry age-related macular degeneration (AMD)/geographic atrophy (GA) is PST-611, a first-in-class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator. Restoring normal iron homeostasis, transferrin has demonstrated strong beneficial effects in preclinical models, reducing oxidative stress and inflammation and preserving the integrity of the retinal pigment epithelium, with the potential of preventing retinal degeneration and vision loss.¹

AMD’s pathogenesis is complex and involves the dysregulation of iron homeostasis, leading to an excess of free iron, which results in inflammation, oxidative stress, and cell death.¹

The company shared in its press release¹ that the planned PST-611-CT1 clinical trial aims at primarily confirming the favorable safety profile of PST-611 administration and is expected to start Q2 2025, subject to the regulatory greenlight, with readout anticipated end 2025/early 2026.

In addition to the funding that has been committed to these efforts, the Series A financing remains open to new investors, to provide funds to support PST-611 Phase IIa clinical trial preparation and implementation, as well as the development of PulseSight’s wider portfolio of non-viral vectorized therapies including PST-809, a potential first-in-class therapy for wet AMD that comprises a dual-gene plasmid encoding for a potent anti-VEGF, together with decorin, an anti-angiogenic and anti-fibrotic native protein.¹

Reference:

1. PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD. PulseSight Therapeutics SAS. February 13, 2025. Accessed February 18, 2025. https://www.biospace.com/press-releases/pulsesight-therapeutics-announces-first-close-of-its-series-a-financing-to-fund-clinical-development-of-pst-611-in-dry-amd